Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1998;91:383-388
© 1998 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paarlberg, K.
Right arrow Articles by Dekker, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paarlberg, K.
Right arrow Articles by Dekker, G.

Articles

Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: a longitudinal study

KM Paarlberg, CL de Jong, HP van Geijn, GJ van Kamp, AG Heinen, and GA Dekker

OBJECTIVE: To determine normal values of total plasma fibronectin in all three gestational trimesters and to examine 1) whether total plasma fibronectin levels differ between normotensive, hypertensive, and preeclamptic women; and 2) whether total plasma fibronectin may serve as an early marker of pregnancy-induced hypertensive disorders. METHODS: Total plasma fibronectin was measured in 376 nulliparous women once in each trimester of pregnancy. Normotensive controls (n = 222) and subjects with pregnancy-induced hypertensive disorders (n = 154) were identified after delivery. The group with pregnancy-induced hypertensive disorders was subdivided into a gestational hypertensive group (n = 125) and a preeclamptic group (n = 29). A complete total plasma fibronectin data set was obtained from 347 subjects. Trends in total plasma fibronectin values were compared for the different groups and relative risks (RRs) were calculated after optimal cutoff levels had been determined by receiver operating characteristic curves. RESULTS: Total plasma fibronectin values (+/- standard error of the mean) were 227 +/- 3 mg/L in the first, 219 +/- 3 mg/L in the second, and 260 +/- 5 mg/L in the third trimesters in normotensive pregnancies. In the first trimester and persisting throughout pregnancy, total plasma fibronectin levels were significantly higher in patients with pregnancy-induced hypertensive disorders than in controls and showed a sharper increase throughout pregnancy. Increased first-trimester total plasma fibronectin levels result in an RR of 1.4 (95% confidence interval [CI] 1.1, 1.8) of developing a pregnancy-induced hypertensive disorder in general. The RR for the development of preeclampsia was 1.7 (95% CI 0.9, 3.4), which was not significant, when the first-trimester total plasma fibronectin level was above the cutoff level of 240 mg/L. The RR for developing preeclampsia was 3.8 (95% CI 1.8, 8.0) when the second-trimester total plasma fibronectin level increased above 230 mg/L. CONCLUSION: The findings of the present study confirm those of previous studies that have found increased total plasma fibronectin levels in pregnancy-induced hypertensive disorders. This study discovered that in these women, total plasma fibronectin levels are elevated in the first trimester. Total plasma fibronectin appears to be a poor predictor of preeclampsia when measured in a general pregnant population. Therefore, total plasma fibronectin should not be used as a routine screening test in a low-risk population. However, obstetricians may use total plasma fibronectin values to help determine the relative risk of developing pregnancy-induced hypertensive disorders.


This article has been cited by other articles:


Home page
 Reproductive SciencesHome page
R. W. Powers, J. M. Catov, L. M. Bodnar, M. J. Gallaher, K. Y. Lain, and J. M. Roberts
Evidence of Endothelial Dysfunction in Preeclampsia and Risk of Adverse Pregnancy Outcome
Reproductive Sciences, April 1, 2008; 15(4): 374 - 381.
[Abstract] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
T. Aydin, F. G. Varol, and N. C. Sayin
Third Trimester Maternal Plasma Total Fibronectin Levels in Pregnancy-Induced Hypertension: Results of a Tertiary Center
Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 33 - 39.
[Abstract] [PDF]

Home page
 Obstet GynecolHome page
D. B. Carr, G. B. McDonald, D. Brateng, M. Desai, C. T. Thach, and T. R. Easterling
The Relationship Between Hemodynamics and Inflammatory Activation in Women at Risk for Preeclampsia
Obstet. Gynecol., December 1, 2001; 98(6): 1109 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Hunter, M. Aitkenhead, C. Caldwell, G. McCracken, D. Wilson, and N. McClure
Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy
Hypertension, December 1, 2000; 36(6): 965 - 969.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
G. M. Lambert-Messerlian, H. M. Silver, F. Petraglia, S. Luisi, I. Pezzani, W. M. Maybruck, W. A. Hogge, K. Hanley-Yanez, J. M. Roberts, L. M. Neveux, et al.
Second-Trimester Levels of Maternal Serum Human Chorionic Gonadotropin and Inhibin A as Predictors of Preeclampsia in the Third Trimester of Pregnancy
Reproductive Sciences, May 1, 2000; 7(3): 170 - 174.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Obstetricians and Gynecologists.